Sellas Life Sciences Group Inc

NASDAQ:SLSUnited States

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Contact Information

Headquarters

7 TIMES SQUARE, SUITE 2503NEW YORK, NY, United States 10036

Phone

646-200-5278

Fax

302-636-5454

Executives

Independent Chairman of the Board

Jane Wasman

President, Chief Executive Officer, Director

Angelos Stergiou

Chief Financial Officer

John Burns

Senior Vice President - Clinical Development

Dragan Cicic

Vice President - Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality

Andrew Elnatan